Article Text

Download PDFPDF
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme
  1. Weifen F Zeng,
  2. Kapila Navaratne,
  3. Richard A Prayson,
  4. Robert J Weil
  1. The Brain Tumor Institute and the Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Correspondence to:
 Dr R Weil
 Brain Tumor Institute, ND4-40 Lerner Research Institute, Clevel and Clinic Foundation, 9500 Euclid Avenue, Cleveland OH 44195, USA; weilr{at}ccf.org

Abstract

Chromosomal abnormalities and genomic instability are common features of, and possible driving forces in, tumorigenesis. Recently, several mitotic proteins that are critical to proper chromosome segregation have been identified. Members of the Aurora kinase family have been identified as having important roles in mitosis; overexpression induces multicellularity and fosters polyploidy. As aneuploidy is a common feature of malignant gliomas, particularly glioblastomas (GBMs), we examined 25 prospectively collected GBMs to assess the role that overexpression of one member of this family, Aurora B, might have in the clinical behaviour of GBMs. Aurora B expression levels were markedly correlated with a shortened survival. Aurora B expression was not directly related to age, tumour proliferation status or to several common molecular changes found in GBMs. These results suggest that Aurora B may be a prognostic feature of impaired survival and a novel therapeutic target in some patients.

  • FISH, fluorescence in situ hybridisation
  • GBM, glioblastoma
  • IHC, immunohistochemistry
  • LTS, long-term survivor
  • STS, short-term survivor

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding: This research was supported by the Melvin Burkhardt chair in neurosurgical oncology and the Karen Colina Wilson research endowment in the Brain Tumor Institute at the Cleveland Clinic Foundation.

  • Competing interests: None.